Previous studies have shown that soluble common c-chain (scc) modulates CD4
It has previously been demonstrated that CD8
1 T cells play a pivotal role in anti-tumor responses to various types of cancer. 1 However, the cytotoxic activity of CD8 1 cytotoxic T lymphocytes (CTLs) is known to be diminished by an immune evasion mechanism of tumors. Recently, we identified sgc as an antagonistic regulator for gc cytokines, including IL-2, IL-7 4 and IL-15, 5 which is important in T cell homeostasis and activation, especially, in the survival, proliferation and effector function of CD8 1 T cells. [6] [7] [8] [9] sgc is generated via alternative splicing of gc mRNA, which can then be translated to a truncated form of membrane gc (mgc), 4 and the secreted sgc protein forms a homodimeric structure that binds directly to IL-2Rb, another subunit of the cytokine receptors, 10 resulting in the inhibition of IL-2 and IL-15 signaling. 4, 5, 11 The proliferation of na€ ıve CD8 1 T cells that is responsible to IL-2 unlike CD4 1 T cells were significantly inhibited by sgc. 4 In previous report, however, whether sgc produced during TCR-stimulation regulates the functional properties of activated CD8 1 T cells has not been determined. TCR-stimulated CD8 1 T cells produces various cytokines that regulate themselves or bystander cells through autocrine or paracrine pathways. 12 The strength and duration of IL-2 signaling during a primary immune response have been shown to be critical on the differentiation and functions of CD8 1 T cells. 13 While suboptimal IL-2 signals during priming induced the reduction of primary and severely impaired secondary expansion, 14, 15 exposure to prolonged, strong IL-2 signals during priming generates short-lived the terminally differentiated effector CD8 1 T cells. [16] [17] [18] Notably, short and intensive IL-2 signals are required to form prolonged functional effector CD8 1 T cells. The other key issue in adoptive cell transfer (ACT) is the maintenance of adaptively transferred effector CD8 1 T cells in the recipient. IL-15 plays a critical role in the survival of effector memory CD8 1 T cells. 6, 7, 19 Therefore, studies on regulatory mechanism of IL-2 and IL-15 signals is pivotal in generation of long-term persistent functional CD8
1 effector T cells in adaptive T cell immunotherapy. 20, 21 In this study, we would like to investigate a new regulatory mechanism of sgc in IL-2 and IL-15 signaling of CD8 1 T cells. Our findings offer novel insights into how immune response and sgc are integrated in the anti-tumor immune responses. Moreover, we suggest sgc as a candidate target to potentiate the in vivo anti-tumor activity of CD8 1 T cells during in vitro priming for adaptive immunotherapy.
Material and Methods

Animals
C57BL/6 (B6) mice were obtained from the Orient Bio, Korea, OT-I and B6.SJL (CD45.1) mice were obtained from the Jackson Laboratory, and gc -/-mice were bred in our own colony. In order to generate a mgcBAC transgenic construct, rpsL-neo counter selection cassette was inserted in the gc gene (exon 5-6-7) of the mice BAC RP23-263O9 vector and the inserted cassette was replaced to the exon 5-7 cDNA of gc, which was injected into the fertilized B6 oocytes to generate mgcBACTg mice (Cyagen, Santa Clara, CA). The gc -/-mice were bred with mgcBACTg or gcTg mice to generate sgcKO or mgcTg mice. The sgcTg mice under control of human CD2 (hCD2) enhancer-promoter and sgcKO mice were bred with OT-I mice to generate OVA 257-264 specific sgc overexpressing or deficient CD8 1 T cells. All animal experiments and used protocols were approved by Pusan National University Institutional Animal Care and Use Committee (PNU-2017-1605). All mice were housed in a specific pathogen-free animal facility at Pusan National University School of Medicine.
Proliferation assay
Na€ ıve CD8 1 responder T cells were labeled with 0.5 mM CFSE (carboxyfluorescein diacetate succinimidyl ester; Invitrogen, Carlsbad, CA) and incubated with human IL-2 (10 mg/ml; Peprotech, Seoul, Korea) for 2 or 3 days. CD8 1 T cells were labeled with 0.5 mM CFSE and stimulated with OVA 257-264 or a-CD3 for 1-3 days.
Cytotoxic assay
OT-I cells were stimulated with 10 ng/ml OVA 
Flow cytometry analysis
The cells were harvested, stained and analyzed via FACS Canto or FACS AriaII (BD biosciences, San Jose, CA). Dead cells were excluded by forward light scatter gating and propidium iodide staining. The data were analyzed using FlowJo version 10 (TreeStar). Antibodies with the following specificities were used for staining: CD45.1 (Ly5.1), TCRb (H57-597), IL-2Rb (TM-b1), granzyme B (NGZB) and isotype control antibodies, all from Thermo Fisher (Waltham, MA); gc (4G3), CD4 (GK1.5 and RM4.5), CD69 (H1.2F3), CD25 (PC61.5), pSTAT5 (pY694) and CD8a (53-6-7) from BD Biosciences (San Jose, CA); Bcl-2 (BCL/10C4) and IFNg (XMG1.2) from BioLegend (San Diego, CA). APC-conjugated H-2K b tetramers loaded with OVA 257-264 and unloaded controls were obtained from the NIH tetramer facility (Emory University, Atlanta, GA Adoptive cell transfer in vivo models sgcKOOT-I, OT-I and sgcTgOT-I cells were stimulated with 10 ng/ml OVA 257-264 for 2 days. Activated OT-I cells (5 or 6 3 10 6 ) were transferred intravenously into B6 mice which EG.7 cells were implanted subcutaneously 2 days ago. Tumor-bearing mice were not conditioned for ACT with a total body irradiation and IL-2 administration. Tumors were followed by caliper measurements few times for week.
In vitro stimulation with IL-15
CD8
1 T cells were incubated with 20 ng/ml recombinant human IL-15 (Peprotech, Rocky Hill, NJ) in the presence or absence of sgc for 3 days. CD8
1 T cells were stained for intracellular Bcl-2 expression. Intracellular Bcl-2 was stained using a Foxp3 staining kit, in accordance with the manufacturer's instructions (ThermoFisher, Waltham, MA). Active caspase-3 induction was determined using CaspGLOW TM fluorescein active caspase-3 staining kit (ThermoFisher, Waltham, MA).
Statistical analysis
The data are shown as the mean 6 SEM. Statistical differences were analyzed by unpaired or paired two-tailed Student's t test. Two-way ANOVA was used for statistical analysis of tumor growth and cytotoxic assay data. p values of <0.05 were considered statistically significant. *p < 0.05, **p < 0.01, *** p < 0.001. All statistical analyses were performed using GraphPad Prism (GraphPad Software).
Results
scc impairs antigen specific CD8
1 T cell responses
We sought to determine the role of sgc in CD8 1 T cell response, as sgc negatively regulated the gc cytokines IL-2 and IL-15 4, 5 which are important in optimal CD8 1 T cell responses. We first examined and compared the kinetics of sgc, IL-2, IFNg, TNFa, CD69 and CD25 expression of CD8 1 T cells following TCR stimulation to clarify regulatory function of sgc in the context of complex cellular immune responses. As previous results showed, 4 sgc, IL-2, IFNg and TNFa level in culture supernatants and CD69 and CD25 surface expression increased time dependently after CD8 1 T cell priming (Fig. 1a) . In order to address whether IL-2 signaling is involved in regulation of sgc expression, a-IL-2 was treated to stimulate CD8 1 T cells. While a-IL-2 inhibited CD25, IFNg and TNFa expression, it failed to inhibit upregulation of sgc and CD69 expression (Fig. 1a) , indicating that CD69 and sgc expression IL-2-independently increased upon TCR stimulation. In order to translate the effect of sgc into the human T cell immunotherapy, we assessed the kinetics of sgc expression in stimulated human CD8
1 T cells and found that human sgc was upregulated upon TCR stimulation similar to mouse CD8 1 T cells (Fig. 1b) . We next examined the functional activity of OVA specific CD8
1 T cells from OT-I mice under treatment of exogenous recombinant sgc. We also used a CFSE dilution assay to check for the proliferation (Fig. 1c) . IFNg production from proliferating OT-I cells was notably reduced by sgc compared with OT-I cells stimulated with OVA 257-264 alone (Fig. 1c) , while there was no significant difference in proliferation (Fig. 1c) , which indicated that sgc regulated TCR-stimulated cytokine production rather than proliferation. Although IL-2 dependent proliferation of CD8
1 T cells was suppressed by sgc ( Fig. 1d ), an inhibition of IL-2 signaling by sgc during priming may affect functional activity of CD8 1 T cells than proliferation. Thus, we addressed the cytotoxic activity of OT-I cells and found that these cells stimulated with OVA 257-264 plus sgc showed a moderate lytic activity against OVA 257-264 /EL4 target cells compared with that of OT-I cells stimulated only with OVA 257-264 (Fig. 1e) . Interestingly, cytotoxicity of OT-I cells on the effector stage was comparable regardless of sgc treatment (Supporting Information Fig. S1 ). Collectively, our results demonstrate that sgc may negatively regulate CD8
1 T cell responses during in vitro priming.
scc deficiency enhances CD8
1 T cell responses via IL-2 signaling Because sgc expression was upregulated time-dependently after TCR stimulation, we wish to assess the effect of upregulated sgc expression during priming. We then generated sgc deficient mice. Although gc -/-gcTg (mgcTg) mice which was achieved by generating a hCD2 mini-cassette-driven membrane gc transgene (gcTg) and then breeding the transgene into gc -/-mice were used as sgc deficient mice, 4 regulatory process of gc expression in mgcTg T cells was not responsible to TCR stimulation. Because of that, a generation of sgc deficient mice, in which the expression of mgc is physiologically regulated with an impaired expression of sgc was required to address the role of sgc during CD8
1 T cell priming. We achieved this by generating a BAC RP23-263O9 replaced endogenous exon 5, 6 and 7 to prespliced exon 5-7 (mgcBACTg) and then breeding the transgene into gc -/-mice ( Fig. 2a , gc -/-mgcBACTg is referred to sgcKO). Genomic PCR analysis showed a DNA fragment of WT (760 bp), mgcBACTg (760 bp and 300 bp), gc -/-(none) and sgcKO (300 bp) (Fig. 2b) . The lack of circulating sgc proteins was confirmed in the serum of sgcKO mice (Fig. 2c) , while the surface gc expression was intact (Fig. 2d) . A concurrent assessment of mgc expression upon TCR stimulation revealed that gc expression was upregulated in the WT and sgcKO CD8
1 T cells but not in mgcTg CD8 1 T cells (Fig. 2d) .
Next, in order to confirm the T cell development and homeostasis in newly generated sgcKO mice, we analyzed the thymus (Supporting Information Fig. S2A ) and the LN 
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(Supporting Information Fig. S2B ) and found that sgc in na€ ıve mice has no effect in T cell development and homeostasis. gc cytokines play an instructive role in the differentiation of CD8 1 effector T cells, thus we wished to know how sgc during in vitro priming would affect CD8 1 T cell function. We stimulated CD8 1 T cells from sgcKO, WT and sgcTg mice with a-CD3 and determined their cytokine expression profiles (Fig. 2e) . The defect of sgc production 
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Role of sgc in anti-tumor CD8 1 T cell responses markedly enhanced IFNg and granzyme B expression than in the WT level or overexpression of sgc (Fig. 2e) , whereas perforin was unaffected by sgc deficiency (data not shown).
Overall IFNg and TNFa levels in culture supernatant was correlatively increased in the absence of sgc (Fig. 2f) , as shown in the proportion of IFNg-producing cells. IL-2 induced by activated sgcKO, WT and sgcTg CD8 1 T cells was not significantly different (Fig. 2f) , indicating that suppressed activity of CD8 1 T cells by sgc result from dampening of IL-2 signaling but not from impaired IL-2 production and IL-2 production by activated T cells was independent on sgc level. To assess IL-2 inhibitory effect of sgc during CD8
1
T cell priming, we analyzed sgcKO CD8 1 T cells using a stimulation in the presence of sgc or a-IL-2 antibodies. The enhanced IFNg and granzyme B production by sgc deficiency was potently suppressed by exogenous sgc and antagonizing IL-2 antibodies (Fig. 2g) . Importantly, while sgc had a similar effect as IL-2 antibodies as it suppressed the level of IFNg and TNFa, co-incubation of sgc and a-IL-2 did not have additive effects (Fig. 2h) To gain further insight into the effects of sgc during CD8 1 T cell priming, we also assessed the functional properties of antigen-specific CD8 1 T cells, using a sgc deficient or overexpressing OT-I mice. CD8 1 T cells from sgcKOOT-I, WT OT-I and sgcTgOT-I mice were stimulated with an OVA 257-264 antigen, and we examined their cytokine expression profiles (Fig. 3a) . sgcKOOT-I cells produced more granzyme B than OT-I and sgcTgOT-I cells, while IFNgproducing cells were present at comparable frequencies (Fig.  3a) , which was consist with previous studies. 14, 18 Next, we addressed a cytotoxic activity using various sgc-expressing OT-I cells and found that sgcKOOT-I cells showed potent lytic activity against OVA 257-264 /EL4 target cells compared with that of OT-I and sgcTgOT-I cells (Fig. 3b) . Collectively, our results demonstrate that moderate improvement of IL-2 signals by sgc deficiency during in vitro priming induces efficient in vitro cytolytic activity to the strong production of granzyme B. (Fig. 4a) . The effects of enhanced killing of sgcKOOT-I cells was further confirmed by significantly reduced tumor mass (Fig. 4b) . These results indicate that the effector CD8 1 T cells generated in the absence of sgc could not only effectively inhibit tumor growth but also markedly promote killing activity against tumors. 
Tumor Immunology and Microenvironment scc deficiency enhances in vivo expansion and functional activity of effector CD8
1 T cells
We administrated the in vitro primed effector CD8 1 T cells intravenously into tumor-bearing mice and measured frequency of transferred-effector CD8 1 T cells in the blood and spleen at intervals after infusion. The overall, transferred effector OT-I cells were generally expanded in the blood over time after the infusion (Fig. 5a) . Notably, sgcKOOT-I effector cells were highly expanded compared with either WT OT-I or sgcTgOT-I over time (Fig. 5b ). Next, we tested the persistence of expanded effector T cells in tumor bearing mice and found that WT OT-I or sgcTgOT-I cells were rarely detected in spleen at Day 35 days after infusion. However, in contrast to the OT-I or sgcTgOT-I cells, sgcKOOT-I cells persisted in the spleen for 35 days at approximately 2% of CD8 1 T cells (Fig. 5c ). As memory CD8
1 cells generated in vivo express high levels of both CD44 and CD122 6 and the IL-15-induced proliferation of CD44 hi CD8
1 T cells in vivo is largely confined to the CD122 hi subpopulation, 7 we tested the frequency of memory CD8
1 T cells with CD44 and CD122 markers and found that most long-lived donor CD8 1 T cells (60-70%) express memory surface phenotype CD44 hi CD122 hi in all groups (Fig. 5c) . We then analyzed the functional activity and memory recall responses of the persisted OT-I cells by detecting the functional cytokine production. We used a short-term stimulation with PMA/Ionomycin to confirm the responses of effector T cells resulting in sgcKOOT-I cells showing a higher ability to produce IFNg and granzyme B than OT-I and sgcTgOT-I cells (Fig. 5d) . These data indicated that donor CD8
1 T cells are remained with memory phenotype but functional property and numbers of CTLs are 
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enhanced in the absence of sgc. For memory responses of OT-I cells, we stimulated the splenocytes with OVA 257-264 antigen and observed a much higher production of IFNg and granzyme B of sgcKOOT-I cells than OT-I and sgcTgOT-I cells (Fig. 5d) . To further assess the impact of sgc deficiency in memory responses of CD8 1 T cells, we analyzed memory responses of CD8 1 T cells from in vivo immunized mice.
OT-I mice were immunized with CFA/OVA 257-264, and isolated CD8 1 T cells were restimulated with a relevant antigen, 14 days after immunization. CD8 1 T cells in immunized sgcKOOT-I mice showed a stronger activation phenotype with a greater frequency of IFNg 1 granzyme B 1 cells than either OT-I or sgcTgOT-I cells (Fig. 5e) . Therefore, these data demonstrate that the priming of effector CD8 1 T cells in the absence of sgc promoted their expansion, persistence and function, resulting in an improvement of anti-tumor T cell responses.
scc interferes with IL-15 signaling in CD8 1 T cells
Next, we sought to determine the underlying mechanism for the potentiated persistence of transferred sgcKOOT-I cells.
Homeostasis and survival of effector memory CD8 1 T cells depends on IL-15, and the enhanced persistence could be a direct consequence of the augmented IL-15 signaling. Thus, we assessed the expression of surface gc and IL-2Rb, which are the signaling units of a functional IL-15 receptor. Their levels on the membrane surface of CD8 1 T cells were comparable between WT and sgcKO or sgcTg (Fig. 6a) . IL-15 signaling is pivotal for memory CD8 1 T cells because it upregulates the expression of anti-apoptotic factor. 22 Bcl-2 is one of the key pro-survival factors in the downstream of IL-15 signaling, 23 we found that IL-15-induced Bcl-2 expression was strikingly impaired in the presence of exogenous sgc (Fig. 6b) . Moreover, we have now assessed expression of proapoptotic factors, such as Bad, Bax, Bid and Bim, and found that Bad, Bid and Bim level except for Bax was significantly reduced upon IL-15 stimulation (Supporting Information Fig.  S3 ). Although the results were not statistically significant, sgc displayed a tendency to rescue their expression reduced by IL-15. Further studies are required to confirm the nonsignificant difference. Decreased Bcl-2 expression was associated with increased susceptibility to apoptosis, and elevated caspase-3 activity was indicative of increased cell death. 24 Indeed, sgc treatment inhibited the pro-survival effect of IL-15 during in vitro culture of CD8 1 T cell, as shown by a significantly increased frequency of EtBr 1 active-capase3 1 cells (Fig. 6c) . Thus, sgc inhibits the persistence of effector CD8 1 T cells in the recipient mice, presumably by inhibiting IL-15 signaling.
Discussion
There has been much evidence to support the notion that immune cells, particularly cytotoxic CD8
1 T lymphocytes (CTLs), can induce potent anti-tumor responses as well as induce substantial tumor rejection in mouse models and cancer patients. 25, 26 Thus, a number of studies on CD8 1 T cell immunity are profoundly linked to their development, activation, expansion and survival. gc family of cytokines, which includes IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, are important in CTL responses. 27, 28 As IL-2 and IL-15 are particularly important for the regulation of their life and death, 29, 30 many studies have been focused on the regulation of their signaling. In this study, we investigated the role of sgc on the effector functions and survival of CD8
1 T cells against tumor. We have previously shown an antagonistic effect of sgc on IL-2 and IL-15 signaling. 4, 5 Consistent with this, we found that sgc dampened IL-2 and IL-15 signaling and induced the suboptimal effector functions and survival of CD8
1 T cells by showing that sgc could inhibit the function of TCR stimulated CD8
1 T cells, not only by significantly reducing the production of Th1 cytokine IFNg but also by inflammatory cytokines TNFa and granzyme B; sgc deficient CD8 1 T cells demonstrated superior anti-tumor responses and persistence in recipient mice.
The receptors of IL-2 and IL-15 are heterotrimeric, which shares gc and IL-2Rb with a unique receptor subunit, IL2Ra and IL-15Ra, 31 respectively. As both receptor cores contain the same IL-2Rb and gc, signal pathway induced by IL-2 and IL-15 involves a common JAK-STAT signaling cascade. 28 IL-2 and IL-15 have several similar roles in T cell immunity, as they use common receptor components, gc/IL2Rb, and signaling molecules, Jak1/Jak3/STAT5, including the proliferation, survival and effector function of NK, NKT, T and B cells. 28 However, IL-2 and IL-15 have distinct functions, and these differences are especially pivotal in homeostasis and responses of CD8 1 T cells. 30 The nonredundant roles of IL-2 have generally been understood to the generation of functional effector CTLs and an induction of optimal secondary proliferative responses. 9, 32 More recent studies showed that the functional differentiation of CD8 1 T cells can be profoundly influenced by the magnitude and duration of IL-2 signals. 18 In fact, it has been reported that excessive or suboptimal IL-2 signals during priming differentiates short-lived terminal effector CD8 1 T cells 33 or leads to impaired primary and secondary expansion, respectively, resulting in reduced anti-tumor responses. 21 Many studies have documented the effect of exogenous cytokines that affect the magnitude and quality of the CD8 1 effector T cells generated during in vitro priming, because a prerequisite for successful ACT is the generation of sufficient numbers of effector T cells. Exogenous IL-2 treatment is a well-known way to generate substantial numbers of effector CTLs. 9, 14, 31, 32 Indeed, TCR-stimulated CD8 1 T cells in the absence of IL-2R signaling in vitro impaired CTL differentiation, including lack of granzyme B expression, and limited proliferation. [14] [15] [16] Thus, long-term exposure and high dose of IL-2 are required to obtain a large numbers of tumor reactive T cells for ACT; however, T cells rapidly and terminally differentiate under this condition, and they fail to trigger tumor regression with poor survival capabilities. 21 By contrast, IL-15
has been shown to act as a superior stimulus and an antiapoptotic factor for promoting the maintenance of memory and effector T cells after adoptive transfer of tumor-specific T cells and to inhibit IL-2-induced AICD in Il15 transgenic mice. 36 For that reason, although interest in using exogenous IL-15 rather than IL-2 for immunotherapy has increased, importance of IL-2 signal in effector T cells cannot be overlooked. Our findings indicate a dual function of sgc during an in vitro generation of the effector CTLs for the optimal in vivo persistence of CTLs with anti-tumor responses. we suggest that controlling sgc might have a dual effect, generating (i) more effective CTLs with (ii) enhanced survival capacities for successful ACT.
As the sgc is identical to ectodomain of mgc that ligand binding is mediated but does not directly bind free IL-2 produced in vitro CD8
1 T cell priming, we considered it unlikely that sgc would impair IL-2 signaling by ligand sequestration. Indeed, we found that sgc directly interacts with membrane IL-2 receptors and interfere with ligand/ receptor interaction. Altogether with current study and our previous reports, 4, 5, 38 we propose that sgc produced upon TCR stimulation competes with mgc to bind IL-2Rb and opposes formation of signaling competent heterotrimeric IL-2/IL-2Rb/mgc complexes. In fact, recent reports using immunofluorescence co-patching and FRET analysis documented that mgc and IL-2Rb already can form 1:1 heterodimeric complexes even in the absence of IL-2. 39 Accordingly, sgc also could be pre-associated with IL-2Rb, and sgc in serum or media could compete with mgc for IL-2Rb occupancy. In sum, sgc expression would result in pre-assembly of cytokine receptor dimers that can bind ligands but are signaling incompetent and increased sgc levels would increase the fraction of such non-productive cytokine receptors, resulting in enhanced suppressor activity.
The in vivo anti-tumor efficacy of ACT has commonly been tested in some models in which effector T cells are adoptively transferred to lymphopenic mice. As CD8 1 T cells transferred into lymphopenic host mice undergo vigorous homeostatic proliferation and acquire the phenotypic and functional features of effector memory T cells, [40] [41] [42] it is problematic to confirm the functional and survival efficacies of transferred effector T cells in this model. In our model, we have ruled out the potential complications due to either cytokines and homeostatic proliferation by cutting the exogenous in vitro and in vivo IL-2 treatment and by transferring the effector cells into tumor-bearing mice with a normal pool of lymphocytes. In this regard, although ACT alone to treat tumors without preparations that enhance anti-tumor efficacy of ACT was used in this study, sgc blockade could enable the effector cells to establish persistent anti-tumor responses.
This study highlights the sgc as a key factor for regulating CTL responses. sgc, which is generated by alternative splicing, negatively regulates CTL responses via the inhibition of IL-2 and IL-15 signaling. Our findings offer novel insights into how immune responses and sgc are integrated in antitumor immune responses. We suggest sgc as a candidate for molecular target to control tumors in an immune suppressive condition.
